Skip to main content

Table 2 Baseline characteristics of followed and non-followed subjects in the TLGS cohort, Tehran Lipid and Glucose Study (1999–2014)

From: Application of survival tree analysis for exploration of potential interactions between predictors of incident chronic kidney disease: a 15-year follow-up study

Variables

Total

n = 10,333

Followed

n = 8238

Non-followed

n = 2095

Difference (95% CI)

Age (years)

39.24 (13.64)

39.29 (13.25)

39.02 (15.07)

0.27 (− 0.38, 0.92)

Total length of stay in the city (years)

32.68 (13.47)

32.88 (13.08)

31.88 (14.90)

1.00 (0.30, 1.69)

BMI (kg/m2)

26.44 (4.77)

26.50 (4.67)

26.20 (5.14)

0.29 (0.04, 0.54)

Waist circumference (cm)

87.23 (12.38)

87.42 (12.28)

86.47 (12.75)

0.95 (0.33, 1.56)

Wrist circumference (cm)

16.69 (1.34)

16.71 (1.34)

16.64 (1.32)

0.07 (0.01, 0.13)

Hip circumference (cm)

100.18 (9.34)

100.28 (9.17)

99.78 (9.98)

0.50 (0.02, 0.98)

FPG (mmol/l)

5.29 (1.59)

5.27 (1.53)

5.38 (1.83)

− 0.10 (− 0.19, − 0.01)

TG (mmol/l)

1.83 (1.33)

1.84 (1.34)

1.80 (1.33)

0.04 (− 0.02, 0.11)

TC (mmol/l)

5.16 (1.15)

5.17 (1.14)

5.11 (1.17)

0.05 (0.01, 0.11)

HDL-C (mmol/l)

1.07 (0.28)

1.07 (0.28)

1.07 (0.28)

− 0.00 (− 0.01, 0.01)

eGFR (mL/min/1.73 m2)

75.70 (10.53)

75.59 (10.49)

76.15 (10.70)

− 0.56 (− 1.07, − 0.04)

SBP (mmHg)

116.59 (17.40)

116.49 (17.05)

116.99 (18.74)

− 0.50 (− 1.33, 0.34)

DBP (mmHg)

76.34 (10.65)

76.39 (10.60)

76.15 (10.81)

0.23 (− 0.27, 0.75)

Heart rate (beats/min)

79.28 (11.54)

79.25 (11.50)

79.40 (11.71)

− 0.15 (− 0.71, 0.40)

Educationa

 Level 1 (illiterate)

2202 (21.3)

1754 (21.3)

448 (21.4)

0.0086 (− 0.0119, 0.0289)

 Level 2 (< 9 years)

6000 (58.1)

4831 (58.6)

1169 (55.8)

 Level 3 (9–12 years)

1520 (14.7)

1203 (14.6)

317 (15.1)

 Level 4 (> 12 years)

611 (5.9)

450 (5.5)

161 (7.7)

Marital status

 Single

1814 (17.6)

1337 (16.2)

477 (22.8)

0.0759 (0.0540, 0.0979)

 Married

8149 (78.9)

6625 (80.4)

1524 (72.7)

 Divorced/widowed

370 (3.6)

276 (3.4)

94 (4.5)

FH-CVD in female relatives

840 (8.1)

669 (8.1)

171 (8.2)

− 0.0009 (− 0.0293, 0.0275)

FH-CVD in male relatives

843 (8.2)

657 (8.0)

186 (8.9)

− 0.019 (− 0.048, 0.009)

FHD in first-degree relatives

2801 (27.1)

2255 (27.4)

546 (26.1)

0.0107 (− 0.0066, 0.0280)

PAL

 Inactiveb

6827 (70.5)

5458 (70.7)

1369 (69.9)

− 0.0063 (− 0.0239, 0.0114)

Smoking

 Never

7684 (75.6)

6207 (76.5)

1477 (72.1)

− 0.0001 (− 0.0305, 0.0304)

 Past

702 (6.9)

567 (7.0)

135 (6.6)

 Current

1776 (17.5)

1339 (16.5)

437 (21.3)

Use of blood lipid lowering drugs

231 (2.2)

177 (2.1)

54 (2.6)

− 0.0317 (− 0.0869, 0.0234)

Use of blood glucose lowering drugs

320 (3.1)

234 (2.8)

86 (4.1)

− 0.0681 (− 0.1173, − 0.0189)

Use of anti hypertensive drugs

434 (4.2)

335 (4.1)

99 (4.7)

− 0.0265 (− 0.0667, 0.0138)

Use of aspirin

933 (9.0)

717 (8.7)

216 (10.3)

− 0.0316 (− 0.0599, -0.0034)

Use of diuretics

120 (1.2)

93 (1.1)

27 (1.3)

− 0.0225 (− 0.0976, 0.0526)

Prevalence CVD

324 (3.1)

219 (2.7)

105 (5.0)

− 0.1253 (− 0.1768, -0.0737)

  1. Figures are either mean (SD) or n (%) for continuously and categorically distributed variables, respectively
  2. TLGS Tehran Lipid and Glucose Study, BMI body mass index, FPG fasting plasma glucose, TG triglyceride, TC total cholesterol, HDL-C HDL cholesterol, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, FH-CVD family history of premature cardiovascular disease, FHD family history of diabetes mellitus, PAL physical activity level, CVD cardiovascular disease
  3. aThe adjusted risk differences (95% CI) between followed and non-followed participants regarding categorical variables were estimated by logistic regression adjrr command in stata
  4. bDoing exercise or labor less than three times a week or performing activities achieving < 600 metabolic equivalent of task (MET)